INHIBITOR Therapeutics
1992
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
INTI
STOCK SYMBOL
$0.04
SHARE PRICE
(As of Monday Closing)
Description
Inhibitor Therapeutics Inc, formerly HedgePath Pharmaceuticals Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Website
Formerly Known As
Hedgepath Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Stock Exchange
PINX
Primary Office
- 324 South Hyde Park Avenue
- Suite 350
- Tampa, FL 33606
- United States
+1 (813) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore INHIBITOR Therapeutics’s full profile, request a free trial.
INHIBITOR Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $14.1M | $0.05 | -$0.01 | 18.4K | 370M |
INHIBITOR Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 24,237 | 24,718 | 91,882 | 134,277 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,440) | (4,564) | (5,119) | (7,022) |
| Net Income | (3,424) | (4,550) | (5,101) | (7,000) |
| Total Assets | 1,484 | 1,233 | 768 | 7,338 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
INHIBITOR Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.
Request full access to PitchBookINHIBITOR Therapeutics Competitors (33)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ra Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
| 00000 000000000000 | Corporate Backed or Acquired | Carlsbad, CA | 000 | 0000 | 00000000000 | 0000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 0000000 0000000000 | Corporation | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
INHIBITOR Therapeutics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.
Request full access to PitchBookINHIBITOR Therapeutics Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Nicholas Virca | President and Chief Executive Officer | ||
| Garrison Hasara | Chief Financial Officer and Treasurer | ||
| James McNulty | Secretary, Compliance Officer and Treasurer |
INHIBITOR Therapeutics Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 000000 00000 00. | INHIBITOR Therapeutics | Board Member | 000 0000 |